Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More
Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
News
Tag: Health Canada
Priority Review by Health Canada
Last Updated: 06/22/2024 by Steve Leave a Comment
Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More
Category: News, Top Slider, What's New Tags: 2024, Acadia, Health Canada
Health Canada Accepts a New Drug Submission
Last Updated: 04/24/2024 by Steve Leave a Comment
Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
Category: Latest Research, News, Press Releases, Top Slider Tags: 2024, Acadia, Health Canada, Trofinetide